They also argued that the makers of name-brand Zantac were liable for the wording on ranitidine labels.
“They had direct control over the warning labels on those generic products,” the plaintiffs argued. “As a matter of law, the generic manufacturers were bound by the brand name manufacturers’ labeling decisions.”
The companies’ dismissal memoranda note that a judge rubbished similar cancer claims in a sprawling Florida multidistrict litigation. The breakup of the multidistrict litigation case paved the way for smaller groups of plaintiffs to sue individually.
Sanofi has repeatedly stated that “there is no reliable scientific evidence that Zantac can cause cancer.”
“Sanofi believes that none of these cases should proceed to trial,” the company said in a recent statement about similar litigation in Delaware. “Sanofi remains committed to its defense and to the safety of Zantac and will continue to vigorously defend itself against these claims, which the medical, scientific, and regulatory communities have extensively evaluated and have found to be without merit.”
